Location History:
- Osaka, JP (2012)
- Kanagawa, JP (2015 - 2021)
Company Filing History:
Years Active: 2012-2021
Title: Innovations by Shinkichi Suzuki in Pharmacology
Introduction
Shinkichi Suzuki is a prominent inventor based in Kanagawa, Japan, recognized for his significant contributions in the field of pharmacology with an impressive portfolio of 25 patents. His work primarily focuses on compounds that modulate cholinergic muscarinic receptors, which are crucial in the treatment of various neurodegenerative disorders.
Latest Patents
Suzuki's recent innovations include two notable patents. The first patent addresses "2,3-dihydro-4H-1,3-benzoxazin-4-one derivatives as modulators of cholinergic muscarinic M1 receptor." This compound acts as a positive allosteric modulator of the M1 receptor and may serve as a prophylactic or therapeutic drug for a range of conditions, including Alzheimer's disease, schizophrenia, pain, sleep disorders, Parkinson's disease dementia, and dementia with Lewy bodies. The second patent pertains to a "Nitrogen-containing heterocyclic compound," which shares similar applications and promises therapeutic potential for the same medical conditions.
Career Highlights
Shinkichi Suzuki is currently associated with Takeda Pharmaceutical Company Limited, where he has made significant contributions to drug development and innovation. His work reflects a deep understanding of pharmacology, especially in targeting cholinergic pathways to mitigate serious neurological disorders. His success is a testament to his dedication to enhancing patient care through innovative solutions.
Collaborations
Throughout his career, Suzuki has collaborated with esteemed colleagues, including Masami Yamada and Takahiro Sugimoto. These partnerships have facilitated the exchange of ideas and expertise, further enriching his research and the development of effective pharmacological agents.
Conclusion
In summary, Shinkichi Suzuki's inventive contributions to pharmacology highlight his role as a key innovator in the field of medicinal chemistry. With a focus on therapeutic strategies for complex neurological disorders, his patents represent a significant advancement toward potential treatments that can improve the quality of life for patients worldwide.